Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Gemcitabine‐based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second‐line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, alloste...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Ikeda, Masafumi, Ioka, Tatsuya, Fukutomi, Akira, Morizane, Chigusa, Kasuga, Akiyoshi, Takahashi, Hideaki, Todaka, Akiko, Okusaka, Takuji, Creasy, Caretha L., Gorman, Shelby, Felitsky, Daniel J., Kobayashi, Mikiro, Zhang, Fanghong, Furuse, Junji
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765304/
https://ncbi.nlm.nih.gov/pubmed/29121415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13438
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky